Building 4, Yuewang Wisdom Valley, 1463 Wuzhong Avenue, Wuzhong District, Suzhou, China
A CD19 CAR-T vector (pHi-HV01-EF1α-CD19 CAR) with a specific killing function and convenient identification of infection efficiency has been developed by Jiangsu Hillgene based on the second-generation CAR-T technology. The vector is added with the costimulatory domain, 4-1BB, which prolongs the survival time of CAR-T cells and promotes the proliferation of cells, and the kanamycin resistance is also modified so that it can meet the requirements of domestic and foreign regulations and policies.
Advantages
CD19 CAR-T lentiviral packaging is performed using Jiangsu Hillgene’s VSV-G envelope four-plasmid system. VSV-G pseudotyped LVVs adhered to and entered the cell by recognizing the low-density lipoprotein receptor (LDL-R) on the cell surface. The prevalence of LDL-R on the cell membrane enabled VSV-G to allow LVVs to enter a variety of cells. At present, VSV-G pseudotyped LVVs are widely used in the transduction of human and other mammalian cells, and CD19 CAR-T can efficiently and specifically kill CD19-positive cells, which provides a very good research tool for preclinical studies of gene/cell therapy and is of great significance for promoting the development of gene/cell therapy.
CD19 CAR-T Vector Design
CD19 CAR-T Lentivirus Preparation Process
CD19 CAR-T Lentivirus Quality Standard
*Specific products to be sold are determined according to the actual batch.
Data
1. CD19 CAR-T Cell Preparation Process
2. CAR-T Detection Data
3. CAR-T Cell Quality Standard
Product Order Information
Building 4, Yuewang Wisdom Valley, 1463 Wuzhong Avenue, Wuzhong District, Suzhou, China